explore -WSS

explore

author：hotspot 2025-09-06 04:12:44 - browse：38

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： H5N1 communication has been strictly for the birds

focus

WSS

Study: Adult vaccinations pay for themselves in societal benefits

Use wet bulb globe temperature, not heat index, to protect workers

Congressmen charge Covid hearing ‘could have been an email’

Novo Nordisk to expand supply of Wegovy for U.S. patients

First recipient of genetically engineered pig kidney has died

CDC wastewater surveillance dashboard to track bird flu hotspots

explore

explore

explore

Affirmative action in medical school literally saved lives

Do digital therapeutics have a future in medicine?

New air purifier tech could be key to improving indoor air quality

What we need to know about Arena Bioworks

Medicare details structure of new drug price negotiation program

Covid misinformation case heads to Supreme Court

At least 13 dead in Texas as scorching temps continue

What nurses really want: sufficient staffing for patient care

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA drug safety: Singulair case shows systemic surveillance flaws

explore

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Do digital therapeutics have a future in medicine?

Juul spent big to court Black leaders to promote its e

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Covid misinformation case heads to Supreme Court

Commercial surrogacy can be ethical, despite pope’s claims

explore

focus

focus

hotspot